Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease
APL Bioengineering · 01.03.2026 · 10 (1)
DOI: 10.1063/5.0297897 ↗Kurz gefasst
Fachartikel in der Zeitschrift APL Bioengineering, online erschienen am 21.01.2026. Verfasst von Taj Yeruva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIBIB NIH HHS, National Institute of Biomedical Imaging and Bioengineering.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic condition characterized by recurrent gastrointestinal inflammation that requires long-term therapeutic intervention. While anti-TNF-α monoclonal antibodies (mAbs) are effective in maintaining remission in IBD, systemic delivery is associated with immunosuppression, poor targeting efficiency, and high cost. To address these limitations, we developed a synthetic mucin-based hydrogel for localized delivery of TNF-α-targeting mAbs. Mucins are heavily glycosylated biopolymers that naturally bind antimicrobial and anti-inflammatory proteins, making them well-suited for local biologic drug delivery at mucosal sites. Synthetic mucin-based hydrogels were formed by cross-linking mucin harvested from porcine small intestine with a 4-arm PEG-thiol and loaded with mAbs to evaluate biocompatibility, antibody release kinetics, and therapeutic efficacy. In vitro studies confirmed cytocompatibility of mucin-based hydrogels and demonstrated diffusion-dependent release of full-length IgG antibodies, with enhanced release under proteolytic conditions simulating the gastrointestinal environment. Moreover, mucin-based hydrogels alone were found to modulate macrophage activation in a stiffness dependent manner and dampen inflammation in lipopolysaccharide (LPS)-stimulated macrophages. Treatment of LPS-stimulated macrophages with mAb-loaded hydrogels reduced pro-inflammatory cytokine production and macrophage activation, confirming retention of mAb bioactivity. Compared to antibodies administered in solution, in vivo biodistribution studies revealed greater absorption of antibodies when loaded in mucin-based hydrogels and administered via enema in trinitrobenzene sulfonic acid-induced colitis mice, likely due to enhanced adhesion to mucosal epithelium and slowed intestinal clearance. This study demonstrates the potential of mucin-based hydrogels as a platform for local mAb delivery in IBD, enabling targeted immunosuppression while minimizing systemic exposure.
Autor:innen und Institutionen
- Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, USA.
ORCID-Profile: Taj Yeruva, Michele Kaluzienski, Shadin Doski, Katharina Maisel, Gregg A Duncan
Förderung
- NHLBI NIH HHS
- NIBIB NIH HHS
- National Institute of Biomedical Imaging and Bioengineering
- National Heart, Lung, and Blood Institute
- National Science Foundation Graduate Research Fellowship Program
Zitieren
APA
Yeruva, T., Yang, S., Kaluzienski, M., Louisthelmy, R., Doski, S., Maisel, K., & Duncan, G. A. (2026). Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease. APL Bioengineering, 10(1). https://doi.org/10.1063/5.0297897
Vancouver
Yeruva T, Yang S, Kaluzienski M, Louisthelmy R, Doski S, Maisel K, et al. Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease. APL Bioengineering. 2026;10(1). doi:10.1063/5.0297897
BibTeX
@article{Yeruva2026,
author = {Yeruva, Taj and Yang, Sydney and Kaluzienski, Michele and Louisthelmy, Rebecca and Doski, Shadin and Maisel, Katharina and Duncan, Gregg A},
title = {Synthetic mucus biomaterials enable localized therapeutic antibody delivery in inflammatory bowel disease},
journal = {APL Bioengineering},
year = {2026},
volume = {10},
number = {1},
doi = {10.1063/5.0297897}
}
EUVIMED